Jinguo Wang1, Sheng Xie1, Jun Liu1, Tao Li1, Wanrong Wang1, Ziping Xie2. 1. Department of Andrology, Renmin Hospital, Hubei University of Medicine, No. 39 Chaoyang Middle Road, Maojian District, Shiyan, 442000, Hubei, People's Republic of China. 2. Department of Andrology, Renmin Hospital, Hubei University of Medicine, No. 39 Chaoyang Middle Road, Maojian District, Shiyan, 442000, Hubei, People's Republic of China. xieziping12121@163.com.
Abstract
BACKGROUND: Emerging evidence suggests that microRNAs (miRNAs) play multiple roles in human cancers through regulating mRNAs and distinct pathways. This paper focused on the functions of miR-4429 in prostate cancer (PCa) progression and the molecules involved. METHODS: Expression of miR-4429 in PCa tissues and cells was determined. Upregulation of miR-4429 was introduced in PCa cells to examine its role in the malignant behaviors of cells. The putative target mRNA of miR-4429 involved in PCa progression was predicted from a bioinformatic system and validated through luciferase assays. Overexpression of distal-less homeobox 1 (DLX1) was further induced in cells to validate its implication in miR-4429-mediated events. The activity of Wnt/β-catenin pathway was determined. RESULTS: miR-4429 was poorly expressed in PCa tissues and cells. Artificial upregulation of miR-4429 significantly reduced proliferation, growth, invasion, migration and resistance to death of cancer cells and inactivated the Wnt/β-catenin pathway. DLX1 mRNA was found as a target of miR-4429. Upregulation of DLX1 restored the malignant behaviors of PCa cells which were initially suppressed by miR-4429, and it activated the Wnt/β-catenin pathway. CONCLUSION: Our study highlights that miR-4429 inhibits the growth of PCa cells by down-regulating DLX1 and inactivating the Wnt/β-catenin pathway. This finding may offer novel insights into PCa treatment.
BACKGROUND: Emerging evidence suggests that microRNAs (miRNAs) play multiple roles in humancancers through regulating mRNAs and distinct pathways. This paper focused on the functions of miR-4429 in prostate cancer (PCa) progression and the molecules involved. METHODS: Expression of miR-4429 in PCa tissues and cells was determined. Upregulation of miR-4429 was introduced in PCa cells to examine its role in the malignant behaviors of cells. The putative target mRNA of miR-4429 involved in PCa progression was predicted from a bioinformatic system and validated through luciferase assays. Overexpression of distal-less homeobox 1 (DLX1) was further induced in cells to validate its implication in miR-4429-mediated events. The activity of Wnt/β-catenin pathway was determined. RESULTS:miR-4429 was poorly expressed in PCa tissues and cells. Artificial upregulation of miR-4429 significantly reduced proliferation, growth, invasion, migration and resistance to death of cancer cells and inactivated the Wnt/β-catenin pathway. DLX1 mRNA was found as a target of miR-4429. Upregulation of DLX1 restored the malignant behaviors of PCa cells which were initially suppressed by miR-4429, and it activated the Wnt/β-catenin pathway. CONCLUSION: Our study highlights that miR-4429 inhibits the growth of PCa cells by down-regulating DLX1 and inactivating the Wnt/β-catenin pathway. This finding may offer novel insights into PCa treatment.
Authors: Leander Van Neste; Rianne J Hendriks; Siebren Dijkstra; Geert Trooskens; Erik B Cornel; Sander A Jannink; Hans de Jong; Daphne Hessels; Frank P Smit; Willem J G Melchers; Gisèle H J M Leyten; Theo M de Reijke; Henk Vergunst; Paul Kil; Ben C Knipscheer; Christina A Hulsbergen-van de Kaa; Peter F A Mulders; Inge M van Oort; Wim Van Criekinge; Jack A Schalken Journal: Eur Urol Date: 2016-04-20 Impact factor: 20.096
Authors: Cindy Ke Zhou; David P Check; Joannie Lortet-Tieulent; Mathieu Laversanne; Ahmedin Jemal; Jacques Ferlay; Freddie Bray; Michael B Cook; Susan S Devesa Journal: Int J Cancer Date: 2015-11-27 Impact factor: 7.396
Authors: Soo Jin Jung; Sangtaek Oh; Geun Taek Lee; Jaeil Chung; Kweonsik Min; Jangho Yoon; Wansuk Kim; Dong Soo Ryu; Isaac Yi Kim; Dong Il Kang Journal: World J Mens Health Date: 2013-04-23 Impact factor: 5.400
Authors: D W Chan; W W Y Hui; J J Wang; M M H Yung; L M N Hui; Y Qin; R R Liang; T H Y Leung; D Xu; K K L Chan; K-M Yao; B K Tsang; H Y S Ngan Journal: Oncogene Date: 2016-09-05 Impact factor: 9.867